Azurity Revives Oral Obesity Drug After HTA Rejection and Incretin Disruption

Azurity Pharmaceuticals Acquires Naltrexone HCl/Bupropion HCl for Obesity Management

Azurity Pharmaceuticals highlights its strategy of identifying and revitalizing established medicines whose market value has shifted. The company recently acquired naltrexone HCl/bupropion HCl, an oral combination therapy for chronic weight management, which was initially approved by the FDA in September 2014 but whose original manufacturer later filed for Chapter 11. Azurity believes the obesity treatment landscape has fundamentally changed, largely due to the impact of GLP-1s, leading to increased patient awareness, physician engagement, and an evolved commercial infrastructure, creating new opportunities for previously underperforming assets.

• Strategic Acquisition of Established Asset: Azurity Pharmaceuticals acquired naltrexone HCl/bupropion HCl and a related portfolio in June 2026. This move is central to Azurity's business model, which focuses on re-evaluating established medicines whose market potential may have been previously underestimated or constrained by outdated market conditions, rather than inherent issues with the drug's efficacy or safety.
• Transformation of the Obesity Market: The press release details how the obesity treatment environment has undergone a significant transformation since naltrexone HCl/bupropion HCl's initial FDA approval in 2014. The emergence of GLP-1 medications is cited as a key catalyst, fundamentally changing the public and medical discourse around obesity, leading to dramatically increased patient awareness, greater physician engagement, and a more robust commercial infrastructure for weight management solutions.
• Azurity's Value Creation Model: Azurity's core strategy involves identifying unrealized value within established medicines and therapeutic categories. This process requires a rigorous analysis of the medicine itself, the current market dynamics, unmet patient needs, and the competitive landscape. The company leverages its comprehensive capabilities in development, regulatory affairs, commercialization, and market access to unlock new value, potentially through formulation innovation, expanded access, or revised commercialization models.

Beyond Obesity: Naltrexone HCl/Bupropion HCl's Broader Potential

Beyond obesity, fixed-dose naltrexone/bupropion is being explored for stimulant use disorders and binge-eating disorder, building on μ-opioid receptor antagonism of mesolimbic reinforcement with bupropion catecholaminergic effects. Evaluated populations include concurrent cocaine use disorder with class I obesity, methamphetamine use disorder, and binge-eating disorder with comorbid obesity.

The Transformed Obesity Treatment Landscape: A New Opportunity

Incretin hormone agonists have redefined pharmacotherapy for obesity, offering substantial weight reduction and cardiometabolic benefits beyond lifestyle modification. Agents like liraglutide, semaglutide, and tirzepatide supported by key clinical trials such as Satiety and Clinical Adipose Liraglutide Evidence (SCALE), Semaglutide Treatment Effect in People with Obesity (STEP) program trials, and Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) have demonstrated remarkable efficacy in promoting weight loss and improving metabolic outcomes. Weight loss was dose-dependent: semaglutide 2.4 mg/wk. -14.9% to -15.2%, tirzepatide 15-18.5%, liraglutide -8.8-11%, dulaglutide -1.3-2.0%, and dual GIP/GLP-1 therapy up to 21.5%. Liraglutide 3.0 mg daily induced a weight loss of 6-8%, Semaglutide 2.4 mg once weekly improved weight loss to about 12-15%, while the dual GIP/GLP-1 receptor agonist tirzepatide once weekly has induced a weight loss of about 20% in obese people without diabetes.

The landscape has expanded from injectable formulations to oral and next-generation multi-agonists. Until recently, almost all incretin-based therapies have been injectable formulations due to limitations in absorption and bioavailability, with two agents (oral semaglutide and orforglipron) having obtained FDA approval. In phase 3 trials, oral semaglutide and orforglipron have demonstrated clinically significant weight loss efficacy of > 10% with an adverse-event profile consistent with the GLP-1 class, and oral semaglutide is additionally approved for secondary cardiovascular risk reduction. Novel therapies under investigation include dual and triple incretin agonists categorized by mechanisms of action into oral glucagon-like peptide-1 (GLP-1) receptor agonists, triple agonists (targeting GLP-1, glucose-dependent insulinotropic polypeptide [GIP], and glucagon receptors), and glucagon receptor-GLP-1 receptor co-agonists, as well as the triple agonist retatrutide (GIP/GLP-1/glucagon), a combination of semaglutide and cagrilintide (a long-acting amylin analogue), and small molecule GLP-1 receptor agonists (e.g., oral danuglipron). Glycemic and cardiometabolic improvements included HbA1c reductions up to -1.78%, SBP reductions -5.28 to -7.8 mmHg, and LDL-C decreases up to -11 mg/dL.

These advances are challenging the position of bariatric surgery and establishing cardiovascular protection as a treatment goal. Historically, bariatric surgery has been the most effective intervention for achieving sustained weight loss, with substantial weight loss maintained over 9 years and ranging from 26.5 ± 2.3% to 33.0 ± 2.0% between 1 and 8 years following surgery, while recent advances including GLP-1 receptor agonists, dual and triple incretin agonists, and amylin-based combination therapies have demonstrated unprecedented efficacy, with some agents inducing 15-25% weight loss, approaching outcomes once exclusive to surgical intervention. Multiple cardiovascular outcome trials demonstrated that GLP-1 RAs cause a significant reduction in major adverse cardiovascular events, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, in patients with T2DM, and a meta-analysis of 21 trials encompassing 99,592 patients found conclusive, high certainty, evidence that GLP-1 RAs reduced all-cause death (IRR 0.88, 95% CI 0.84-0.92, NNT=121), CV death (IRR 0.87, 95% CI 0.81-0.92, NNT=170) and MACE (IRR 0.87, 95% CI 0.83-0.91, NNT=66). Gastrointestinal adverse events were common (nausea 14.7-62%, vomiting 3-30.3%, diarrhoea 5-34.9%), while serious events, pancreatitis, and gallbladder complications were rare, with treatment discontinuation generally <15%, although discontinuation of therapy is frequently followed by significant weight regain with a large proportion occurring during the early post-cessation period.

Azurity's Strategy: Addressing Unmet Needs in a Changing Market

Recent literature reframes obesity pharmacotherapy beyond injectable GLP-1 RAs toward integrated metabolic, neuroendocrine, and body-composition-focused disease modification. Durability of weight loss, tolerability and access barriers, and distinct high-risk phenotypes are driving next-generation development and personalized algorithms.

• Durability after GLP-1 RA discontinuation and weight-loss plateau: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual/triple co-agonists produce mean weight losses of 10-30%, yet up to 65% of users discontinue GLP-1 RAs within a year of initiation, and randomized controlled trials demonstrate that two-thirds of lost weight is typically regained within a year of discontinuation, with reversal of cardiometabolic improvements. Modeling anchored to average baseline demographics estimated weight loss peaked at 24.0% (95% CI: 22.6-25.4) by week 96, reducing weight from 108 kg (BMI 40.0 kg/m) to 82.9 kg (BMI 33.0 kg/m), with a plateau persisting for ∼78 weeks despite continued treatment, energy intake decreased 32.1% during the first 4 weeks then rose to match energy expenditure by week 98 (2500 kcal, vs. 2508 kcal, respectively), and a 5.3% weight loss reversal after discontinuation (week 176).

• Next-generation multi-receptor, oral, and lean-mass-preserving approaches for variability, plateau, and access: Triple agonists such as retatrutide achieve weight reductions of 20-24%, while dual GLP-1/glucagon agonists like survodutide and mazdutide show strong efficacy with particular promise for metabolic-associated steatotic liver disease. Oral GLP-1 agonists, including orforglipron, offer comparable efficacy to injectables while potentially improving global accessibility by eliminating cold-chain requirements and simplifying manufacturing; Maridebart cafraglutide, combining GLP-1 agonism with glucose-dependent insulinotropic polypeptide (GIP) antagonism, enables once-monthly dosing; the amylin pathway has re-emerged through long-acting analogs (cagrilintide, eloralintide) and unimolecular co-agonists (amycretin), achieving weight reductions up to 24%; body composition optimization through agents like bimagrumab addresses lean mass preservation during potent anorectic therapy.

• Pediatric, adolescent, and precision monogenic/syndromic populations: Trials of liraglutide, phentermine/topiramate ER, semaglutide, and setmelanotide have led to FDA and/or EMA approval, with the 2023 American Academy of Pediatrics Clinical Practice Guideline recommendation that pediatric health care providers should offer AOM to youth ages ≥12 years with obesity, including special populations with monogenic obesity, Bardet Biedl syndrome, Prader Willi syndrome, and hypothalamic obesity. Personalized approaches, including setmelanotide for monogenic obesity, exemplify precision pharmacotherapy, with critical priorities including phenotype-stratified trials, long-term safety surveillance, pediatric obesity research, and implementation science to ensure equitable global access.

• Cardiometabolic and comorbidity-defined populations: Approximately 20-40% of patients with HF have T2D, while 30-40% are obese (Body Mass Index ≥30 kg/m²), and 45-63% have CKD; among 264,571 patients with HFpEF, 55.7% had obesity, 52.5% had metabolic syndrome, 42.5% had both, and 34.3% had neither. Being obese is a major risk factor for HFpEF, with increasing focus on inter-tissue communication between adipose tissue and the heart in obesity-associated HFpEF, and multidisciplinary management of coexisting heart failure, chronic kidney disease, type 2 diabetes, and obesity to address insulin resistance, chronic inflammation, neurohormonal activation, and endothelial dysfunction.

• Post-bariatric and post-procedure weight regain and nutritional risk: Mean WR at 10 years was 28% (±25), higher in SG vs. RYGB (41.37% vs. 26.17%, p = 0.03), with 56.7% categorized as Regainers (WR > 20%); in a double-blinded, randomized pilot (n = 16) roughly 3 years after bariatric surgery, body mass index (-1.24 kg/m) and body weight (-3.7 kg) were significantly reduced with canagliflozin therapy versus placebo, with reductions in android (-3.00%) and truncal (-2.67%) fat. Preoperative food addiction was present in 17.6% of 165 patients, with total WL lower at 3 years (-27.1% vs. -31.0%; p = 0.023) driven by greater WR from nadir (+8.3% vs. +1.7%; p = 0.03); diet quality score was the only significant variable associated with weight loss at three years after sleeve gastrectomy, with higher scores associated with greater %EWL and %EBMIL.

• Disparity-affected and perinatal populations: From 2007-2008 to 2017-2020 there was an increase in BMI and obesity prevalence particularly among Black and Hispanic adolescents and those from low- and middle-income families, with Black and Hispanic adolescents having 22% (APR = 1.22; 95% CI, 1.06-1.40) and 19% (APR = 1.19; 95% CI, 1.05-1.36) greater risk of being obese versus White adolescents. Pre-pregnancy overweight and obese conditions increased the odds of hypertension in Black (2 ½ times) and White (> 3 ½ times) mothers and increased the odds of GDM (3-7 times), while three out of four people who give birth retain excess weight at 1-year post-pregnancy, with Black and Hispanic/Latina/o/x birthing people more likely to begin pregnancy overweight or obese and to retain excess weight.

Oral Obesity Therapy: A Second Chance Amidst GLP-1 Dominance

Azurity Pharmaceuticals' strategic acquisition of naltrexone/bupropion (NB) marks a calculated effort to re-introduce an established oral obesity therapy into a market fundamentally reshaped by recent advancements. The widespread impact of GLP-1 receptor agonists has not only elevated patient and physician awareness of obesity as a treatable chronic disease but also matured the commercial infrastructure for weight management, creating a potentially more receptive environment for all anti-obesity medications.

NB offers a distinct pharmacological approach, combining bupropion's dopamine and norepinephrine reuptake inhibition with naltrexone's opioid receptor antagonism. This dual mechanism targets both homeostatic appetite regulation and the hedonic, reward-based aspects of eating. Clinical trials have consistently demonstrated NB's ability to achieve clinically meaningful weight loss, typically 3.2-5.2% placebo-subtracted, alongside improvements in cardiometabolic markers such as HbA1c, triglycerides, and HDL-C. Its oral formulation and unique mechanism position it as a valuable option, particularly for patients who may not tolerate or respond optimally to injectable GLP-1s, or those with specific eating behaviors driven by reward pathways.

However, Azurity faces significant challenges. The market is now dominated by GLP-1s, which offer substantially greater weight loss, with newer agents achieving 12-20% reductions. This efficacy gap could limit NB's market penetration, especially as patients and providers increasingly seek maximal weight reduction. Furthermore, NB's known adverse event profile, particularly gastrointestinal issues like nausea and constipation, has historically led to high discontinuation rates, a risk that persists. Despite these hurdles, the evolving understanding of obesity as a complex disease, potentially benefiting from combination pharmacotherapy targeting multiple gut-brain pathways, could create new opportunities for NB. Its established safety and efficacy, coupled with a potentially lower cost profile, might appeal to a segment of the market, especially in primary care settings or for patients with specific comorbidities. The success of this re-launch will depend on Azurity's ability to effectively differentiate NB and integrate it into a comprehensive obesity management paradigm.